Partner With Us NRI

Company details

6M Return -26.74%
1Y Return -33.99%
Mkt Cap.(Cr) 344.77
Volume 1,385
Div Yield 0.00%
OI Chg %
Volume 1,385

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 603.51 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,081.38 -37,247.74
LAST 3M 71,111.08 -54,074.79
LAST 6M 141,746.37 -188,969.09
LAST 12M 212,995.89 -183,256.64


  • About Company
  • Company Info
  • Listing Info
  • Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA. Ind-Swift Laboratories Ltd was incorporated in the year 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India. In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company. During the year 2003-04, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They launched four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (anti-hyperlipidemic), Anastrazole (oncology) and Nitazoxanide (anti-diarroheal). In January 2, 2004, the company incorporated a wholly owned subsidiary, namely Ind-Swift Laboratories Inc in USA to strengthen the company`s presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations. During the year 2004-05, the company expanded the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market. During the year 2005-06, the company completed and commissioned their new plant at Samba in Jammu & Kashmir to manufacture products for the domestic markets. Also, they set up a new state of the art Research & Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA. During the year, the company launched new products namely, Letrozole, Anastrozole (Anti-Cancer) Venlafaxine (Anti-Depressants) Lavofloxacin (Anti-Biotic) Quetipine & Aripirazole (Anti-Pshychotic) in the market. They entered into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to focus on the marketing of the products in Middle East & Iran. During the year 2006-07, the company expanded the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids. During the year 2007-08, the company entered into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mint-based products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.

Read More

Registered Address

SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

Tel : 91-0172-5061850/2730920
Email : investor:indswiftlabs.com
Website : http://www.indswiftlabs.com


Alankit Assignments Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 532305
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE915B01019

ICICIdirect Ind-Swift Laboratories Ltd FAQ

You can buy Ind-Swift Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ind-Swift Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 27, 2022 04:01 PM the closing price of Ind-Swift Laboratories Ltd was ₹ 58.35.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 27, 2022 04:01 PM, the market cap of Ind-Swift Laboratories Ltd stood at ₹ 344.77.
The latest PE ratio of Ind-Swift Laboratories Ltd as of May 27, 2022 04:01 PM is 11.46
The latest PB ratio of Ind-Swift Laboratories Ltd as of May 27, 2022 04:01 PM is 1.26
The 52-week high of Ind-Swift Laboratories Ltd is ₹ 127.35 while the 52-week low is ₹ 55.60 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote